CN100464759C - 一种具有抗癌活性的中药提取物和它的制备工艺及其应用 - Google Patents
一种具有抗癌活性的中药提取物和它的制备工艺及其应用 Download PDFInfo
- Publication number
- CN100464759C CN100464759C CNB2003101109906A CN200310110990A CN100464759C CN 100464759 C CN100464759 C CN 100464759C CN B2003101109906 A CNB2003101109906 A CN B2003101109906A CN 200310110990 A CN200310110990 A CN 200310110990A CN 100464759 C CN100464759 C CN 100464759C
- Authority
- CN
- China
- Prior art keywords
- extract
- chinese medicine
- radix fissistigmatis
- active anticancer
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000001093 anti-cancer Effects 0.000 title claims abstract description 41
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 239000000284 extract Substances 0.000 title claims description 110
- 229930182490 saponin Natural products 0.000 claims abstract description 67
- 150000007949 saponins Chemical class 0.000 claims abstract description 67
- 239000001397 quillaja saponaria molina bark Substances 0.000 claims abstract description 65
- 238000007670 refining Methods 0.000 claims abstract description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 139
- 239000003814 drug Substances 0.000 claims description 64
- 238000010828 elution Methods 0.000 claims description 39
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 22
- 239000003463 adsorbent Substances 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 14
- 239000011347 resin Substances 0.000 claims description 14
- 229920005989 resin Polymers 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000000287 crude extract Substances 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- HWJHWSBFPPPIPD-UHFFFAOYSA-N ethoxyethane;propan-2-one Chemical compound CC(C)=O.CCOCC HWJHWSBFPPPIPD-UHFFFAOYSA-N 0.000 claims description 3
- 239000012535 impurity Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000003480 eluent Substances 0.000 claims description 2
- 239000002798 polar solvent Substances 0.000 claims description 2
- 238000012545 processing Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 6
- 241000208327 Apocynaceae Species 0.000 abstract description 3
- 230000009257 reactivity Effects 0.000 abstract 2
- 241001125690 Marsdenia tenacissima Species 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000017709 saponins Nutrition 0.000 description 56
- 239000000706 filtrate Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 229940079593 drug Drugs 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010992 reflux Methods 0.000 description 7
- 208000005718 Stomach Neoplasms Diseases 0.000 description 6
- 206010017758 gastric cancer Diseases 0.000 description 6
- 201000011549 stomach cancer Diseases 0.000 description 6
- 231100000331 toxic Toxicity 0.000 description 6
- 230000002588 toxic effect Effects 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 229960004397 cyclophosphamide Drugs 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000001694 spray drying Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229930182494 ginsenoside Natural products 0.000 description 3
- 229940089161 ginsenoside Drugs 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 238000004064 recycling Methods 0.000 description 3
- 239000007901 soft capsule Substances 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 241001189830 Fissistigma Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 238000012449 Kunming mouse Methods 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- -1 transfusion Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241001247900 Marsdenia Species 0.000 description 1
- 241000124079 Mylabris Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 102000011759 adducin Human genes 0.000 description 1
- 108010076723 adducin Proteins 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000003443 bladder cell Anatomy 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 238000003810 ethyl acetate extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960002949 fluorouracil Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- HAVJATCHLFRDHY-JZTSUELASA-N harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@](O)(CCC(C)(C)O)CC(=O)OC)[C@@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-JZTSUELASA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000003061 neural cell Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101109906A CN100464759C (zh) | 2003-11-21 | 2003-11-21 | 一种具有抗癌活性的中药提取物和它的制备工艺及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2003101109906A CN100464759C (zh) | 2003-11-21 | 2003-11-21 | 一种具有抗癌活性的中药提取物和它的制备工艺及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1544032A CN1544032A (zh) | 2004-11-10 |
CN100464759C true CN100464759C (zh) | 2009-03-04 |
Family
ID=34335860
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2003101109906A Expired - Fee Related CN100464759C (zh) | 2003-11-21 | 2003-11-21 | 一种具有抗癌活性的中药提取物和它的制备工艺及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100464759C (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991629B (zh) * | 2009-08-21 | 2012-10-17 | 江苏正大天晴药业股份有限公司 | 一种乌骨藤皂苷组合物 |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100387234C (zh) * | 2005-07-08 | 2008-05-14 | 张晴龙 | 一种含乌骨藤苷元的药物及其制备方法和应用 |
CN101612183B (zh) * | 2008-06-26 | 2011-12-21 | 江苏正大天晴药业股份有限公司 | 一种乌骨藤皂苷提取物、药物组合物、制备方法及其应用 |
CN102028726A (zh) * | 2010-12-22 | 2011-04-27 | 中国人民解放军第三○二医院 | 中药通关藤提取物及其制备方法和应用 |
CN104083417A (zh) * | 2014-07-21 | 2014-10-08 | 江苏天晟药业有限公司 | 一种用于治疗肝癌的中药组合物及其制备方法 |
CN105418726B (zh) * | 2015-12-25 | 2017-09-12 | 山西省中医药研究院 | 一种通关藤总皂苷提取物及其提取方法 |
CN106421154A (zh) * | 2016-11-29 | 2017-02-22 | 丁明 | 一种具有修复细胞、抗衰老、抗癌功能的沉香中药组合物、中药制剂及其制备方法 |
CN111690034A (zh) * | 2020-07-07 | 2020-09-22 | 南京宸翔医药研究有限责任公司 | 一种数字化绿色化智能化高纯度通关藤成分群和通关藤苷h的制备方法及其药物组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076859A (zh) * | 1992-03-30 | 1993-10-06 | 河南省新乡市前卫制药厂 | 消癌平有效成分的提取及剂型制备 |
-
2003
- 2003-11-21 CN CNB2003101109906A patent/CN100464759C/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1076859A (zh) * | 1992-03-30 | 1993-10-06 | 河南省新乡市前卫制药厂 | 消癌平有效成分的提取及剂型制备 |
Non-Patent Citations (4)
Title |
---|
乌骨藤抗肿瘤作用的初步试验. 武汉以血缘学报,第4期. 1976 |
乌骨藤抗肿瘤作用的初步试验. 武汉以血缘学报,第4期. 1976 * |
消癌平治疗晚期恶性肿瘤32例. 胡赤丁.医药导报,第20卷第10期. 2001 |
消癌平治疗晚期恶性肿瘤32例. 胡赤丁.医药导报,第20卷第10期. 2001 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101991629B (zh) * | 2009-08-21 | 2012-10-17 | 江苏正大天晴药业股份有限公司 | 一种乌骨藤皂苷组合物 |
Also Published As
Publication number | Publication date |
---|---|
CN1544032A (zh) | 2004-11-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102258563B (zh) | 一种抗癌药物组合物和一种中药组合物 | |
JPS5936619A (ja) | 制癌補助剤 | |
CN103768534A (zh) | 一种具有抗肿瘤活性的中药组合物 | |
CN102552580A (zh) | 一种治疗尿路结石和小便不利口服药物的组方及制备工艺 | |
CN102078511B (zh) | 一种用于促进白细胞生成的药物 | |
CN100464759C (zh) | 一种具有抗癌活性的中药提取物和它的制备工艺及其应用 | |
CN102008650A (zh) | 一种治疗肿瘤的复方中药制剂及其制备方法 | |
CN101711848B (zh) | 一种辅助治疗肿瘤的中药组合物 | |
CN102078569A (zh) | 一种治疗肝癌的中药制剂及其制备方法 | |
CN102861193A (zh) | 一种治疗胃癌的中药组合物 | |
CN102028924B (zh) | 一种用于晚期胃癌的药物组合物 | |
CN101773532B (zh) | 一种天名精总内酯提取物 | |
KR0160108B1 (ko) | 조각자나무로부터 추출한 생약 성분으로 된 항암제 | |
CN101391004B (zh) | 一种用于晚期食管癌的药物组合物 | |
CN101411779B (zh) | 一种治疗肝癌的中药有效部位组合物及其制备方法 | |
CN101007052B (zh) | 一种抗肿瘤药物及其制备方法 | |
CN101485716B (zh) | 一种治疗放射损伤药物及其制备方法 | |
CN101007056B (zh) | 抗肿瘤药物组合物及其制备方法 | |
CN108186794B (zh) | 一种治疗肺癌的中药组合物及其制备方法和应用 | |
CN102188580B (zh) | 治疗乳腺小叶增生的中药外用药组合物和巴布膏剂及制备方法 | |
CN112022896A (zh) | 一种抗肿瘤中药复方软胶囊制剂及其制备方法和应用 | |
CN100475248C (zh) | 一种治疗子宫出血的药物及其制备工艺 | |
CN101357212B (zh) | 一种复方斑蝥注射制剂及其制备方法 | |
CN101716225B (zh) | 一种治疗肝癌的药物及其制备方法 | |
CN102058668A (zh) | 一种治疗原发性血小板减少的中药制剂 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUIZHOU LIANSHENG PHARMACEUTICAL CO., LTD. |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20101008 Address after: 610041, 2, building 6, building 7, 12, wash Bridge Street, No. 6-11, Sichuan, Chengdu, Wuhou District Co-patentee after: Guizhou Vigour Pharmaceutical Co., Ltd. Patentee after: Li Wenjun Address before: 610041, 2, building 6, building 7, 12, wash Bridge Street, No. 6-11, Sichuan, Chengdu, Wuhou District Patentee before: Li Wenjun |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20090304 Termination date: 20141121 |
|
EXPY | Termination of patent right or utility model |